¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : Á¦Ç° À¯Çü, ¿¬·É, »ùÇà À¯Çü, °Ë»ç À¯Çü, ±â¼ú, ¿ëµµ, À¯Åë°æ·Î, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(-2032³â)
Global Point-of-Care Testing for Women Health Market Research by Product, by Age, by Sample Type, by Test Type, by Technology, by Application, by Distribution Channel, by End User, and by Region Forecast till 2032
»óǰÄÚµå : 1797670
¸®¼­Ä¡»ç : Market Research Future
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 350 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,967,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù.
US $ 5,950 £Ü 8,374,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ ±â¾÷ ³» 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù.
US $ 7,250 £Ü 10,204,000
PDF & Excel (Enterprise License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÌ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇϸç, Àμ⠰¡´ÉÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 6.26%ÀÇ °ßÁ¶ÇÑ ¼ºÀå¼¼¸¦ º¸À̸ç 2032³â¿¡´Â 287¾ï 7,000¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿©¼º °Ç°­ POC °Ë»ç´Â »ý½Ä °Ç°­, °¨¿°, Àӽаü·Ã ÇÕº´Áõ°ú °°Àº ½É°¢ÇÑ Áúȯ¿¡ ´ëÇÑ Áï°¢ÀûÀ̰í ÈÞ´ë °¡´ÉÇÑ °á°ú¸¦ Á¦°øÇÏ´Â ´Ù¸ñÀûÀÇ °£ÆíÇÑ Áø´Ü µµ±¸ÀÔ´Ï´Ù. óÀ½¿¡´Â Àå¾ÖÀÎÀ» À§ÇØ °³¹ßµÇ¾úÁö¸¸, ÇöÀç´Â º´¿ø, Ŭ¸®´Ð, °¡Á¤¿¡¼­µµ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Å¼Ó¼º°ú ´õºÒ¾î Àú·ÅÇÑ °¡°Ý°ú ³ôÀº ½Å·Ú¼ºÀ¸·Î ÀÎÇØ Àüü ¿¹¹æ ÀÇ·á ¹× ÁßÁõÈ­ ÀÌÀüÀÇ Á¶±â ÀÇ·á °³ÀÔ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù.

¼ºº´, ¿ä·Î°¨¿°Áõ, HPV µî ¿©¼º¿¡°Ô ÈçÇÑ ÁúȯÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½Å¼ÓÇÑ °Ë»ç µµ±¸ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. POC °Ë»ç´Â ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â °á°ú¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °úÁ¦¿¡ ´ëÀÀÇϰí Á¶±â Áø´Ü ¹× °³ÀÔÀ» Áö¿øÇÕ´Ï´Ù. ¿©¼ºÀÇ °Ç°­Àº Àû½Ã Ä¡·á¿Í Á¢±Ù °¡´ÉÇÑ °Ë»ç ¼Ö·ç¼Ç¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªº° ºÐ¼®

ºÏ¹Ì ½ÃÀåÀº ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â °Ë»ç¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä¸¦ ¹è°æÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ³ôÀº ÀÎÁöµµ¿Í Àß Á¤ºñµÈ ÀÇ·á½Ã½ºÅÛ¿¡ ÈûÀÔ¾î º´¿ø»Ó¸¸ ¾Æ´Ï¶ó ÀçÅÃÀÇ·á ȯ°æ¿¡¼­µµ Æø³Ð°Ô Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. 2023³â ºÏ¹Ì ½ÃÀå¿¡¼­´Â ¹Ì±¹ÀÌ 57¾ï 3,544¸¸ ´Þ·¯, ij³ª´Ù°¡ 8¾ï 8,972¸¸ ´Þ·¯, ¸ß½ÃÄÚ°¡ 4¾ï 2,632¸¸ ´Þ·¯ ½ÃÀå ±Ô¸ð¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À¯·´ ½ÃÀå¿¡¼­´Â Çõ½ÅÀÌ È°¹ßÇÏ°Ô ÀϾ°í ÀÖÀ¸¸ç, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. »ý½Ä °Ç°­¿¡¼­ ¸¸¼º Áúȯ¿¡ À̸£±â±îÁö Áúº´ÀÇ Á¶±â ¹ß°ßÀ» ÁÖ¿ä ¸ñÀûÀ¸·Î ÇÏ´Â ÃÖ÷´Ü Áø´Ü Ç÷§ÆûÀÇ È°¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. 2023³â¿¡´Â µ¶ÀÏÀÌ 12¾ï 2,006¸¸ ´Þ·¯, ¿µ±¹ÀÌ 9¾ï 6,019¸¸ ´Þ·¯, ÇÁ¶û½º°¡ 7¾ï 7,511¸¸ ´Þ·¯·Î À¯·´ »óÀ§ 3À§¸¦ Â÷ÁöÇß½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, Àεµ, µ¿³²¾Æ½Ã¾ÆÀÇ ÀÇ·á Á¢±Ù¼º È®´ë¿¡ ÈûÀÔ¾î °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå ÀáÀç·ÂÀ» º¸À̰í ÀÖ½À´Ï´Ù. 2023³â¿¡´Â Áß±¹(7¾ï 5,165¸¸ ´Þ·¯), Àεµ(6¾ï 3,481¸¸ ´Þ·¯), ÀϺ»(6¾ï 731¸¸ ´Þ·¯)ÀÌ ÁÖ¿ä ½ÃÀåÀ» Çü¼ºÇß½À´Ï´Ù. Àӽаü·Ã ÇÕº´Áõ°ú ¸¸¼ºÁúȯ Áõ°¡·Î POCT ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¿©¼º °Ç°­ °ü·Ã POC °Ë»ç(POC Test) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå Á¤ÀÇ¿Í °³¿ä, ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °¢Á¾ ¿µÇâ¿äÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø, °¢Á¾ ºÎ¹®º°/Áö¿ªº°/ÁÖ¿ä ±¹°¡º° ºÐ¼®, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå ½ÃÀå ¿äÀÎ ºÐ¼®

Á¦6Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : Á¦Ç°º°

Á¦7Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : ¿¬·Éº°

Á¦8Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : »ùÇà À¯Çüº°

Á¦9Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : °Ë»ç À¯Çüº°

Á¦10Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : ±â¼úº°

Á¦11Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : ¿ëµµº°

Á¦12Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : À¯Åë ä³Îº°

Á¦13Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦14Àå ¼¼°èÀÇ ¿©¼º °Ç°­ POC °Ë»ç ½ÃÀå : Áö¿ªº°

Á¦15Àå °æÀï ±¸µµ

Á¦16Àå ±â¾÷ °³¿ä

Á¦17Àå µ¥ÀÌÅÍ Àοë

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Point-of-Care Testing for Women Health Market Research by Product (Instruments/ Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, White Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti- Mullerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-Stimulating Hormone Test, Luteinizing Hormone Test, B-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-Cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections, Fertility Conditions, Pregnancy Testing, Others), by Distribution Channel (Offline, Online), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032

Industry Overview

The Global Point-of-Care Testing for Women's Health Market is forecasted to expand to USD 28.77 billion by 2032, reflecting a steady 6.26% CAGR during 2024-2032. POCT for women's health is a multipurpose, easy-to-access diagnostic tool giving immediate and on-the-go results of critical conditions, such as reproductive health, infectious diseases, and pregnancy-related complications. Originally intended for the disabled, these tests are also accessible at hospitals, clinics, or simply at home. Their rapidity, and at the same time, good affordability and reliability allow them to become keys in the whole preventive care and early medical intervention process serious cases.

Growing cases of sexually transmitted infections, urinary tract infections, and HPV among women highlight the urgent need for rapid detection tools. POC testing addresses this gap with quick and reliable results, supporting early diagnosis and intervention. The rising infection burden is propelling adoption, as women's health outcomes depend on timely treatment and accessible testing solutions.

Key Company Development

Swiss Precision Diagnostics GmbH has demonstrated consistent innovation in advancing diagnostic solutions for women's health. In August 2023, the company launched the Clearblue Menopause Stage Indicator, a first-of-its-kind home-use product that evaluates menopause stages by integrating urinary FSH measurements with age and cycle data. This innovation empowers women with greater understanding of reproductive transitions, fostering informed health decisions. Complementing this milestone, SPD in August 2020 implemented the Matrix Gemini LIMS to optimize data management in pregnancy studies. This technology enhanced accessibility, streamlined laboratory workflows, and improved biobank operations, reflecting the company's strong emphasis on digital transformation. These strategic moves reinforce SPD's leadership in combining product innovation and advanced technologies to deliver precision-driven women's health diagnostics.

Key Players

Major players in the global point-of-care testing for women health market are Swiss Precision Diagnostics GmbH (SPD), Wondfo, Church & Dwight Co., Inc., Hangzhou Singclean, Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, Innovita Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., and Chungdo Pharm Co., Ltd.

Report Attribute Details

Market Size 2023 USD 16,627.22 Million

Market Size 2032 USD 28,768.16 Million

CAGR (2024-2032) 6.26%

Base Year 2023

Market Forecast Period 2024-2032

Historical Data 2019-2024

Industry Segmentations CAGR (2024-2032)

By Product: Instruments/ Devices - 7.72%, Reagents & Kits - 5.97%.

By Age: Adolescent - 8.18%, Adult - 6.20%.

By Sample Type: Serum - 5.27%, Plasma - 4.30%.

By Test Type: Testosterone Test - 4.12%, Estradiol Test - 3.53%.

By Technology: Colloidal Gold Lateral Flow Assays - 7.19%, Fluorescence Immunoassays - 5.46%.

By Application: Gestational Diabetes - 5.34%, Vaginal Infection - 4.08%.

By Distribution Channel: Offline - 5.49%, Online - 7.35%.

By End User: Hospitals - 5.42 %, Diagnostic Laboratories - 6.96%.

Regional Analysis

The women's health POCT market in North America rides on the back of consumer demand for quick and reliable testing. High awareness in conjunction with well-organized healthcare systems acts as a springboard for wide use in hospital as well as home-care environments. In 2023, North America's market was led by the US, followed by Canada and Mexico, with respective market values of USD 5,735.44 million, USD 889.72 million, and USD 426.32 million.

Innovation is thriving in the European market, and there is an increasing emphasis on personalized medicine. The use of cutting-edge diagnostic platforms is growing, with the primary objective being early detection of diseases that range from reproductive health to chronic conditions. In 2023, Germany, the UK, and France were the top three European markets, contributing USD 1,220.06 million, USD 906.19 million, and USD 775.11 million.

Asia-Pacific demonstrates remarkable growth potential, propelled by expanding healthcare access in China, India, and Southeast Asia. In 2023, the APAC region China, India, and Japan, is the leading market, with market sizes of USD 751.65 million, USD 634.81 million, and USD 607.31 million. A rising incidence of pregnancy-related complications and chronic illnesses is driving reliance on POCT solutions.

Markets in the Middle East, Africa, and South America are witnessing steady adoption of POCT, largely due to limited access to traditional laboratory infrastructure. Portable diagnostic technologies are emerging as vital tools in addressing reproductive health challenges.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

3 RESEARCH METHODOLOGY

4 MARKET DYNAMICS

5 MARKET FACTOR ANALYSIS

6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT

7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE

8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE

9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE

10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY

11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION

12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL

13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER

14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION

15 COMPETITIVE LANDSCAPE

16 COMPANY PROFILES

17 DATA CITATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â